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Evaluation of Cyclosporin A (CyA) blood concentration is imperative in solid organ transplantation in order to achieve maximal
immunosuppression with the least side effects.
We compared the results of whole blood concentrations of CyA in 50 blood samples simultaneously evaluated by the fluorescent
polarization immune assay (TDx) and the enzymatic competitive immune assay (EMIT 2000).
There was a strong correlation between both kits for any range of CyA blood concentration (R=0.99, p<0.001). The within-run
and between-days coefficient of variation were less than 4% for both assays.
The cost for each CyA measurement was 50% lower for the EMIT assay when compared to the TDx assay.
We concluded that the EMIT is as accurate as the TDx in measuring CyA blood concentration and has the advantage of a lower
cost, as well as the possibility of widespread access to the EMIT methodology in contrast to the TDx equipment, allowing the
laboratory to perform several routines within a working day.
DESCRIPTORS: Cyclosporin A. Enzymatic competitive immune assay. Fluorescent polarized immune assay. Renal
transplantation. Immunosuppression.
Cyclosporin A (CyA) is a major
immunosuppressant used in solid organ
transplantation. Its introduction almost
two decades ago contributed not only
to improvement of the one-year graft
survival rate but also to the increased
half-life of the transplanted organs.
However, CyA is difficult to handle
because of its narrow therapeutic win-
dow and its serious side effects. There-
fore, CyA blood levels are frequently
monitored either by trough levels or by
complete or abbreviated area under the
time/concentration curve (AUC) 1, 2.
A precise assay for measuring CyA
blood levels is mandatory for any
transplant center dealing with this drug.
In our center, CyA was previously
monitored using the polarized immu-
nofluorescence assay TDx (Abbott-
TDx, Abbott Laboratories, Illinois,
USA).
Although extremely accurate in
measuring CyA blood concentrations,
the TDx assay has some drawbacks.
First is that it measures not only the
parent drug but is cross-reactive even
if it occurs to a lesser extent (9.4%).
Second is that TDx methodology re-
quires blood samples to be collected,
stored, and then measured at once, usu-
ally once daily, because the TDx appa-
ratus is usually not functioning the
whole day in most laboratories. The
consequence of this limitation is that
dose adjustments usually are done with
a 24-hour delay. Third is that TDx
technology is not available in most
laboratories and fourth is that the cost
of each TDx measurement is compara-
tively high.
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 The availability in Brazil of the
EMIT 2000 assay (Syva Company-
Dade Behring Inc, Cupertino, CA,
USA), already in use in other coun-
tries3-9, warrants a study comparing
both assays.
In this study, we have compared the
accuracy, costs, easiness, and effi-
ciency of the EMIT 2000 to the TDx
assays for the measurement of whole
blood levels of CyA in renal trans-
planted patients.
METHOD
Blood samples were obtained from
the first patients who needed to have
CyA blood levels measured at our
transplant center. Consecutive patients
were enrolled in the study until a total
of 50 different blood samples could be
collected. Usually at our transplant
center, we measure whole blood levels
of CyA either at 0, 1, 2, and 4 hours,
at 2 and 4 hours, or only at 2 hours af-
ter the morning oral dose, in order to
calculate abbreviated AUC. Therefore,
many blood samples were collected
from the same patient. Each blood
sample was divided into 8 identical
EDTA tubes, and was identified and
stored at 2-8oC for further analysis. All
patients were receiving Sandimmun
Neoral (Novartis, Basel, Switzerland).
Blood samples were simulta-
neously analyzed for both assays, TDx
(Abbott Laboratories, Illinois, USA)
and EMIT 2000 (Syva Company-Dade
Behring Inc, Cupertino, CA, USA).
The TDx assay is a fluorescent po-
larization immunoassay (FPIA) reagent
system for the measurement of CyA in
whole blood. It uses a competitive
binding immunoassay methodology
that allows tracer-labeled antigen
(CyA) and patient antigen to compete
for binding sites on the antibody mol-
ecules. The components in this com-
petitive binding reaction are mono-
clonal antibodies, the patient antigen,
and the antigen labeled with fluores-
cein (tracer-antigen complex). When
competitive binding occurs, the more
tracer-antigen complex binding to the
antibody molecule, the less tracer-an-
tigen complex remains in solution. If
the patient sample contains a low con-
centration of CyA (the patient antigen),
after the competitive binding reaction
reaches a steady state, there is a high
concentration of bound tracer in the re-
action mixture and polarization is high.
The intensity of polarized light is then
measured by the FPIA optical assem-
bler (TDx-FLEX Abbott Laboratories,
Illinois, USA).
The EMIT 2000 cyclosporin-spe-
cific assay is an enzymatic competitive
immune assay using rat monoclonal
antibodies that are highly specific for
CyA. According to the manufacturer,
during the assay, the CyA in whole
blood competes with the CyA in the
enzymatic reagent B labeled with the
enzyme glucose 6-phosphate dehydro-
genase (G6PDH). The free enzyme
then turns the nicotinamide adenine
nucleotide (NAD) into NADH. This
promotes a change in the absorbance
kinetics that can be measured by spec-
trometry (Selectra II Bayerâ ).
The calibration curve of each assay
requires 6 different CyA concentra-
tions to be tested: 0, 50, 100, 200, 350,
and 500 ng/ml for the EMIT and 0,
100, 250, 500, 1000, and 1500 ng/ml
for the TDx. During this study, the cali-
bration curves were checked for 30
consecutive days using low, medium,
and high CyA concentration samples
and proved to be stable for 30 days in
both assays.
For each assay, whole blood con-
centration of CyA was measured in
duplicate (concentration 1 and 2, C1a
and C2a) to obtain a within-run coef-
ficient of variation (CV), either for
TDx or EMIT. Within-run CV was cal-
culated using the equation:
CV% = [100 – (C1a x 100)/C2a] , with
all results transformed into positive val-
ues. Within-run CV was calculated us-
ing the data obtained for the first and
second assay; therefore, the number of
values in the statistic analysis is twice
the number of blood samples.
In order to obtain the between-day
CV, the frozen samples were analyzed
3 days later in a second measurement
also performed in duplicate (C1b and
C2b)). Between-day CV was calcu-
lated using concentration 1 (C1) of
both measurements for each assay, ei-
ther TDx or EMIT, where CV% = [100
- (C1a x 100)/C1b] and transformed
into positive values.
Since many transplant centers still
use the trough levels to monitor CyA
blood concentration, we also analyzed
the correlation between the two assays
when the CyA concentration was
within the range of the clinically used
trough levels (100 – 350 ng/ml).
In the last 2 years, many centers
have been monitoring CyA blood lev-
els according to the maximal concen-
tration (Cmax) that is reached 1-2
hours after an oral dose of Sandimmun
Neoral. The clinically expected range
of these Cmax concentrations is be-
tween 700 and 1600 ng/ml. Because of
this, we also analyzed the CVs and the
correlation between the two assays ob-
tained when CyA blood levels were in
the Cmax range.
The analysis of costs was made us-
ing the last price for the TDx kit ac-
quired by our institution. The price
used for the EMIT 2000 kit was ob-
tained from the Dade-Behring com-
pany in Brazil.
Data is presented as mean ± SD for
parametric data and median (25-75%)
for non-parametric data. A paired t test
was used to compare CyA blood con-
centrations between the two assays
(TDx vs EMIT). The t test was used to
compare within-run and between-day
CV. For non-parametric data, a Mann-
Whitney Rank Sum test was used.
Simple linear regression was per-
formed between CyA concentrations
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obtained with both assays. The data
was analyzed by means of the statisti-
cal software SigmaStat 2.0 (Jandel Sci-
entific, San Rafael, CA, USA).
RESULTS
Fifty blood samples were collected
from 9 different renal transplanted pa-
tients.
In these 50 samples, the range of
CyA concentrations found was in ac-
cordance with those used in clinical
practice. Mean ± SD (minimum and
maximum range) CyA concentration
for the TDx and EMIT assays were
676 + 401 ng/ml (42-1497 ng/ml) and
695 + 450 ng/ml (38-1635 ng/ml), re-
spectively (p=NS). There was an ex-
tremely good correlation between the
two assays as illustrated in figure 1
(R=0.99, p<0.001).
Table 1 summarizes between-day
and within-run CVs obtained in the
100 samples. There were no significant
differences in either of these CVs. In
the CyA blood levels ranging between
100 and 350 ng/ml, a higher CVs was
observed, but it was still not statisti-
cally significant.
Twenty measurements were within
the trough level range. The mean con-
centration (range) for these 20 samples
for TDx and EMIT was 260 + 56 ng/
ml (144 –345) and 227 + 63 ng/ml
(122 – 328) (p=0.10), respectively. The
median (25-75%) within-run CV was
2.9% (1.5 – 4.2%) for TDx when com-
pared to 2.8% (2.1- 4.3%) for EMIT
(p=NS). The mean between-day CV
was 3.7 + 2.4% for TDx and 4.4 +
4.2% (p=NS) for EMIT (p=NS). For
this range of trough levels, the corre-
lation between the concentrations ob-
tained using both assays was also ex-
cellent (R=0.97, p<0.001)), as seen in
figure 2.
Forty-eight CyA measurements
were within the clinically expected
Cmax concentration. Mean CyA blood
levels for these 48 measurements was
1045 + 261 ng/ml (720-1572) for the
TDx assay and 1100+264 (755-1598)
for the EMIT assay (p=ns). There was
a very good correlation between these
two assays in the blood concentrations
measured (R=0.98, p<0.001) (Fig. 3).
The mean within-run CV was
1.9+2.0% for TDx and 1.7+0.9 for the
EMIT (p=NS). The mean between-day
CV was 1.8+1.7% for TDx and
1.3+0.9 for the EMIT (p=NS).
CyA measurement using the EMIT
2000 is less time-consuming than the
TDx assay (16 vs 25 minutes). Also,
the blood volume required is 100 ul
vs150 ul for EMIT-2000 and TDx, re-
spectively.
Each EMIT 2000 kit costs
US$970.00 for 100 tests, while the TDx
Figure 1 – Correlation between CyA whole blood levels measured by the EMIT 2000 and TDx
assays.
Table 1 - Coefficients of variation of fluorescent polarization immunoassay (TDx)
and enzymatic competitive immune assay (EMIT) in the most used CyA blood
concentration ranges in clinical practice.
Within-Run % Between-days %
CyA levels
All values
TDx 2.4+2.1 (0-13) 2.5+2.1 (0-11.6)
n=100 p=ns p=ns
EMIT 2.3+1.7 (0-13) 2.3+2.0 (0-17.1)
100-350 ng/ml
TDx 3.3+2.4 (0.2-10.6) 3.6+2.4 (0-9.1)
n= 20 p=ns p=ns
EMIT 3.6±2.7 (0.5-13.1) 4.4+4.2 (0.9-17.1)
> 700 ng/ml
TDx 1.9+2.0 (0 – 13) 1.8+1.7 (0.1-11.6)
n= 48 p=ns p=0.08
EMIT 1.7+0.9 (0-4.6) 1.3+0.9 (0-5)
Mean + SD (Range), ns: not statistically significant.
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kit for the same number of tests costs
US$2,023.00. Therefore, the cost per
test is US$9.70 for the EMIT 2000 and
US$20.20 for the TDx assay. Although
the cost of calibrators (quantity suffi-
cient for 6 months) is US$808.50 for the
EMIT 2000 and US$367.14 for the
TDx-Abbott, we decided not to take
these values into account because of the
long-lasting stability of calibrators.
DISCUSSION
In this study, we have demonstrated
that the measurement of CyA blood
concentration by the EMIT 2000 assay
is as accurate as measurement by the
TDx assay in renal transplanted pa-
tients.
There was a strong correlation
(R=0.99) between samples measured
simultaneously by both assays (Fig. 1).
Even when we filtered for samples
with high levels, the correlation was
almost perfect (0.97). For the CyA
range of currently used trough levels,
the correlation was also very good
(R=0.98). However, CyA levels mea-
sured by the EMIT 2000 assay tend to
be lower (approximately 50 ng/ml) in
the established range of Cmin. Never-
theless, this variation does not affect
clinical practice.
This high level of correlation be-
tween the EMIT assay and other assays
has already been shown in other stud-
ies9,10,11.
The analysis of the within-run and
between-day CVs showed a very low
variation for both assays either for high
or low CyA blood concentrations. In
fact, as seen in table 1, both CVs were
below 4% for both assays. This low
CV is extremely important for dose ad-
justment, since any increase or de-
crease in CyA blood concentration
higher than 4% is certainly not attrib-
utable to measurements errors.
CyA is broken into many metabo-
lites, some with immunosuppressive
and toxic properties. Because of this,
a consensus conference in 1995 de-
clared that the best assay for CyA
blood analysis is one that specifically
measures the parental drug concentra-
tion only 12. Although in this study we
have not analyzed the cross-reactivity
of the parent drug and the CyA me-
tabolites in either assay, data showing
that the EMIT 2000 assay is more spe-
cific for the parent drug CyA than the
monoclonal fluorescent polarization
immunoassay TDx, when HPLC is
used as the gold standard method, have
been published10,11. Also, the EMIT
2000 assay does not cross-react with
Figure 2 - Correlation between CyA blood levels in the range of trough concentration (Cmin).
Figure 3 - Correlation between CyA whole blood levels for the range of maximal concentration
(Cmax).
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other immunosuppressant drugs, such
as mycophenolate acid, and has less
than 4.6% cross-reactivity with
sirolimus.
Currently, the evaluation of CyA
blood concentration is becoming in-
creasingly necessary in order to moni-
tor the drug therapeutic level and avoid
CyA toxicity. For example, it has been
suggested that a maximal concentration
of CyA (Cmax) of 1200 to 1700 ng/ml
has to be achieved within the first 5
days after renal transplantation in or-
der to minimize the incidence of rejec-
tion. To achieve this, it is necessary to
monitor Cmax almost after each oral
dose and make the dose adjustments
before the next dose. This fine tuning
can only be achieved by using an as-
say that can be performed any time
during the day and with the results ob-
tained before the next dose.
One of the major advantages of the
EMIT 2000 over the TDx, in our opin-
ion, is the fact that the EMIT 2000 as-
say allows the CyA blood concentra-
tion to be measured any time during
the day and not only once or twice
daily as occurs with the TDx assay.
Frequent daily analyses are possible
because, once calibrated, the
SELECTRA II-Italab system is able to
analyze CyA concentration without in-
terrupting the other laboratory routines.
On the other hand, with the TDx tech-
nology, the laboratory has to keep the
TDx-FLEX turned on during the whole
day in order to measure few CyA
samples. Usually, laboratories turn the
TDx-FLEX on, only once a day.
Another aspect of this benefit is
that it extends the possibility of mea-
suring CyA to any laboratory lacking
the TDx technology, which is a great
advantage for the many small trans-
plant centers in Brazil.
The major disadvantage of the
EMIT 2000 assay is that measuring
CyA concentrations over 500 ng/ml re-
quires a dilution of blood samples. This
requirement is particularly important
because CyA maximal concentration
(usually higher than 500 ng/ml) is the
parameter used to monitor immuno-
suppression. It was a surprise then that
the CV obtained in the high concentra-
tion range (> 700 ng/ml) had such a
low variation as shown in table 1.
The other benefit of the EMIT 2000
assay is the lower cost when compared
to the TDx. Each CyA measurement
costs less than half the price of the TDx
measurement. The analysis of costs did
not take into account the calibration kit
costs. Since the calibration curve is
stable for 1 month in both assays and,
for each calibrator kit, there are enough
reagents for a period of 6 months, cali-
bration costs are minimal when the
laboratory performs a large number of
measurements in a 6-month period.
Reducing medical costs is currently
mandatory, particularly with an expen-
sive drug like CyA that needs frequent
monitoring.
In summary, we have shown that
the EMIT 2000 assay for the CyA
blood concentration is an accurate as-
say when compared to the TDx assay.
It has also advantages when compared
with the TDx, which include lower cost
and more accuracy with respect to the
intact drug and the fact that the labo-
ratories can perform many routines
within a day.
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A avaliação da concentração
sanguínea de ciclosporina A (CyA) é
necessária em transplantes de órgãos
sólidos para obter-se máxima imuno-
supressão e mínimos efeitos colaterais.
Nós comparamos os resultados da
concentração de CyA em 50 amostras
sanguíneas analisadas pelos métodos
dos imuno-ensaios de fluorescência
polarizada (TDx) e enzimático compe-
titivo (EMIT 2000).
Houve uma forte correlação entre
ambos métodos para qualquer faixa de
concentração de CyA (R=0.99,
p<0.001). Os coeficientes de variação
intra e interensaio foram menores que
4% para ambos os métodos.
O custo para cada análise de CyA
foi 50% menor para o EMIT em com-
paração com o TDx.
Concluímos que a metodologia
EMIT é tão acurada quanto a de TDx
para dosar CyA em amostras sanguíne-
as. Além disso, a metodologia EMIT é
mais prática para ser realizada e mais
barata, sendo ainda possível adotá-la
para dosagens de CyA em vários ho-
rários de um mesmo dia.
DESCRITORES: Ciclosporina A.
Imuno ensaio de fluorescência
polarizada. Ensaio imuno enzimático
competitivo. Transplante renal.
Imunossupressão.
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